Drug Trial Radar · NCT06718686
Rifaximin SSD in Dementia Trial
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Dec 30, 2024
Primary completion
Oct 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Jasmohan BajajFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Bausch Health Americas, Inc.
- First posted
- Dec 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.
Conditions
- Dementia Alzheimer Type
- Dementia Associated With Cerebrovascular Disease
Interventions
Rifaximin SSD 40 mg IR tabletDrug
Drug therapy vs placebo
PlaceboDrug
Placebo drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in stool and serum short-chain fatty acid levelsTime frame: 10 weeks
- Change in bile acids in stool and serumTime frame: 10 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Richmond VA Medical Center
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.